Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts | Zendy

Massimo Zucchetti | Zendy; Daniela Meco | Zendy; Angela Maria Di Francesco | Zendy; Tiziana Servidei | Zendy; Valentina Patriarca | Zendy; Gabriella Cusano | Zendy; Maurizio D’Incalci | Zendy; Daniele Forestieri | Zendy; Claudio Pisano | Zendy; Riccardo Riccardi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts

Author(s) -

Massimo Zucchetti,

Daniela Meco,

Angela Maria Di Francesco,

Tiziana Servidei,

Valentina Patriarca,

Gabriella Cusano,

Maurizio D’Incalci,

Daniele Forestieri,

Claudio Pisano,

Riccardo Riccardi

Publication year - 2009

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-009-1201-8

Subject(s) - rhabdomyosarcoma , pharmacokinetics , irinotecan , neuroblastoma , pharmacology , medicine , pediatric cancer , cancer , drug , cell culture , cancer research , sarcoma , biology , pathology , colorectal cancer , genetics

This study compared the antitumor activity and the pharmacological profile of gimatecan given orally and irinotecan (CPT-11) on pediatric tumor xenografts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research